# Detection of Either the EML4-ALK Gene Rearrangements or the T790M EGFR Mutation in the Plasma of Advanced NSCLC Patients

> **NCT03236675** · — · UNKNOWN · sponsor: **Exosome Diagnostics, Inc.** · enrollment: 60 (estimated)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03236675
- **Lead sponsor:** Exosome Diagnostics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-03
- **Primary completion:** 2022-02
- **Final completion:** 2022-02
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2021-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03236675

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03236675, "Detection of Either the EML4-ALK Gene Rearrangements or the T790M EGFR Mutation in the Plasma of Advanced NSCLC Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03236675. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*